GeoVax Appoints Dr. Senthil Ranganathan as Vice President, Technical Development and CMC Operations
Recognized Biologics Executive to Oversee Critical Expansion of U.S.-Based Development Capabilities
ATLANTA, GA - April 22, 2025 ( NEWMEDIAWIRE ) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer, today announced the appointment of Senthil Ranganathan, Ph.D. as Vice President, Technical Development and CMC Operations. Dr. Ranganathan brings over 20 years of experience in biologics development to commercialization across vaccines, cell and gene therapies, monoclonal antibodies, and viral vector products.
This appointment comes at a pivotal time for GeoVax as it advances a comprehensive portfolio of infectious disease vaccines and cancer therapies, positioning the Company to address significant unmet medical needs, contributing to biodefense readiness, and improving vaccine and therapeutic equity through innovation and onshoring.
David Dodd, Chairman & CEO of GeoVax, stated: 'We are delighted to welcome Senthil to GeoVax. His track record and expertise in a breadth of biologics development and preparation for registration and subsequent commercialization will support and enhance our progress as we proceed towards the authorization and subsequent commercialization stages for our exciting development portfolio.'
Dr. Ranganathan has held senior leadership roles across industry-leading biopharmaceutical companies, most recently serving as Head of Process Development CMC for the Boston site of National Resilience. He previously led global CMC and manufacturing operations at Athersys, Zymeworks, and Alder Biopharmaceuticals (acquired by Lundbeck Biopharmaceuticals). His career has spanned the development and validation of cell and gene therapies, vaccines, bispecific antibodies, and other biologics—from pre-IND through licensure and commercialization.
He holds a Ph.D. in Biochemistry from Loyola University Chicago and has authored numerous regulatory submissions and publications in support of breakthrough vaccines, biologics, and therapies.
'I am honored to join GeoVax during such a critical stage of the Company's growth and development,' said Dr. Ranganathan. 'I look forward to working with the outstanding GeoVax team as we develop and execute the roadmap that will bring the GeoVax portfolio to benefit patients and communities worldwide.'
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. The Company's lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin(R), having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. The Company is also developing GEO-MVA, a vaccine targeting Mpox and smallpox. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. For more information about the current status of our clinical trials and other updates, visit our website: www.geovax.com.
Forward-Looking Statements
This release contains forward-looking statements regarding GeoVax's business plans. The words 'believe,' 'look forward to,' 'may,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'should,' 'plan,' 'could,' 'target,' 'potential,' 'is likely,' 'will,' 'expect' and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax's immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax's viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax's immuno-oncology products and preventative vaccines will be safe for human use, GeoVax's vaccines will effectively prevent targeted infections in humans, GeoVax's immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control.
Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.
Company Contact:
[email protected]
678-384-7220
Investor Relations Contact:
[email protected]
212-698-8696
View the original release on www.newmediawire.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
13 minutes ago
- Bloomberg
Nomura Flags Risk of Sharp Yen Rally on US-Japan Policy Pressure
Japanese investors pivoting out of US assets as yen yields rise — combined with implicit pressure from Washington over the exchange rate during trade talks — could push the currency about 6% higher against the dollar in the coming months, according to Nomura Holdings, Inc. The investment bank, among Japan's largest, now recommends shorting the greenback versus the yen, targeting a move in the pair to ¥136 by the end of September, from around ¥145 currently. Nomura's Yusuke Miyairi, Yujiro Goto and Dominic Bunning expect that the Bank of Japan 's steady pace of rate hikes, will 'encourage domestic investors to increase more domestic bond than overseas bond exposure,' they wrote in a Friday report to clients.
Miami Herald
16 minutes ago
- Miami Herald
This month could test buyers' hunger for new vehicles as non-tariffed inventories dry up
Consumers' hunger for new vehicles persisted in May, but affordability concerns could cool sales this month as dealerships start running short on cars and SUVs delivered ahead of President Donald Trump's 25% tariffs. Ford Motor Co.'s U.S. sales increased 16% year-over-year last month. Hyundai Motor Co.'s grew 8%, while Kia Corp.'s rose 5%. Subaru Corp. and Mazda Motor Corp., however, did report declines of 10% and 19%, respectively. General Motors Co. and Stellantis NV will report second-quarter sales next month. Spring typically marks a surge in vehicle sales, as tax returns hit bank accounts and the weather warms up. But consumer sentiment has plunged to some of its lowest levels in decades amid frequently changing rules on tariffs, and concerns that vehicle prices could climb later this year have led some consumers to pull forward their purchases. S&P Global Mobility forecasted May sales up 2% compared to a year ago, but predicted sales were slowing to a seasonally adjusted annual rate of 15.7 million vehicles, down from 17.6 million from March to April. "Consumer confidence is down, but the sales are not," said Stephanie Brinley, associate director of research and analysis at S&P's AutoIntelligence. "It doesn't usually work that way." With inventories down and non-tariffed models increasingly eaten up, the "affordability bullet has not come through yet. There's a little bit of wait-and-see for what automakers really do," Brinley added, noting June could start revealing the direction companies choose to take. Some have given consumers confidence that they can wait a bit. Ford, through the July 4 weekend, is offering its customers thousands of dollars per vehicle in discounts typically reserved for its employees, though in early May, it did increase by up to $2,000 the price of its Mexico-built vehicles because of tariffs. Stellantis - the parent of Chrysler, Dodge, Jeep, Ram and other brands - is offering a similar employee discount program, which it has extended through June. Volkswagen AG has said it will hold to its current manufacturer's suggested retail prices through June. GM CEO Mary Barra has said the automaker doesn't expect major price increases. But imports are expected to slow, which will mean less availability of vehicles and encourage price increases, Charlie Chesbrough, senior economist at dealer digital services provider Cox Automotive Inc., said in a May forecast. "As more tariffed products replace existing inventory over the summer," he said, "prices are expected to be pushed higher, leading to slower sales in the coming months." Some dealers are already noticing some wariness. "I haven't seen people this cautious since before, or during, the early stages of COVID," said Jim Walen, the owner of Stellantis and Hyundai showrooms in Seattle. The ports in Seattle look "empty," he said. Major layoffs in Washington by Microsoft Corp. haven't helped business either. Stellantis' employee discount program, however, is a boon: "Anytime you can affect the transaction price, it's a good thing." Meanwhile, some dealers are going to pull back over revenue concerns, Walen said, but he's taking a different approach: "We're very aggressive. We stock a lot, we're part of the community, we advertise a lot." Some pull-ahead sales still seem to be occurring over tariff concerns, but other shoppers are dropping out of the market altogether, said Ivan Drury, director of insights at auto information website Inc. It may still be too early to determine if the circumstances will affect vehicle segments, but for now, there appears to be limited downgrading, as some customers would rather hold off than get a vehicle without certain features. There are also wide-ranging views on tariffs, how they work and the impact they will have, he added: "Not everybody's on the same page." There, however, are some trends. More consumers bought out their leases in May than in April, rather than leasing again. That could be a sign customers are seeking to limit increases to their monthly payments, but it also means they're stepping out of the market, Drury said. He added that inventory is declining, but there's still too much stock - more than 2.5 million vehicles are on dealer lots - to see substantial price increases. "The last time when we had people really get hit with price increases, where it took them back, was when we were down to 1 million units," Drury said. "And that's where you start to see that crossover between consumers getting a deal versus consumers just dealing and saying, 'OK, fine, I'll pay MSRP. I'll pay above.' " The share of electric vehicles in the market was forecasted to continue slipping. EV share was about 7% in March and April, and S&P was predicting it would be 6.8% in May. Ford EV sales last month were down by a quarter, driven by decreases in the F-150 Lightning pickup and Transit commercial van. Trump has pulled federal funding for EV charging infrastructure and directed his administration to reevaluate greenhouse gas tailpipe emission regulations and incentives that could be construed as an "EV mandate." The U.S. Senate last month also removed a waiver that enabled California and a contingent of states to enforce stricter zero-emission requirements on passenger vehicle sales. The result is an uncertain policy environment around EVs. "They've been trending a little bit down the whole year," Brinley said. "It may be some people looking for an EV in January bought, expecting the incentives to go away, but they're not afraid of that anymore." Rhett Ricart, who has eight new-vehicle storefronts for brands from Ford and Chevrolet to Nissan and Mitsubishi in and near Columbus, Ohio, said tariffs and policy changes are on the minds of EV buyers, but he otherwise describes sales as normal. "A possible tariff scare people had doesn't seem to exist," Ricart said, adding about expectations that Trump or the judicial system will offer some clarity on import taxes: "For any jitteriness, we will hopefully find out if the tariffs stick soon." Copyright (C) 2025, Tribune Content Agency, LLC. Portions copyrighted by the respective providers.
Los Angeles Times
23 minutes ago
- Los Angeles Times
Anaheim Regional Medical Center nurses' union wins pay boost, security upgrades
Registered nurses who work at the Anaheim Regional Medical Center voted to ratify their first-ever labor contract with the hospital on Wednesday night, an agreement they claim will improve patient care. As negotiations carried on, safety remained a top priority for nurses represented by SEIU Local 121RN. The union in April held an info picket outside of the hospital to draw attention to such issues. In the past, nurses and their aides have screened people for weapons and drugs at the hospital's emergency room entrance. While nurses did not gain the walk-through metal detectors they pushed for in bargaining, the hospital has agreed to staff security guards with metal detector wands at different entry points within six months to a year. Security staff will also take over bag searches and provide identification for visitors. 'That's something we're not responsible for anymore,' said Liza Lorenzo, a telemetry nurse who has worked at the hospital for the past 15 years. 'We have more time to do bedside care, as opposed to going through people's belongings, which was not safe for us, as well.' When reached, a spokesperson for AHMC Healthcare, the company that owns the hospital, declined to comment on the contract. The security changes come before Assembly Bill 2975, which the union advocated for and requires hospitals throughout the state to have weapons detection screening policies by March 2027. Nurses also won a minimum 19% pay raise over the four years of the contract. The salary boost comes with additional measures to ensure there are four nurses for every patient at a specialty unit, a ratio mandated by state law. For telemetry units, the nurse-patient ratio is five-to-one. During the pandemic, Lorenzo claimed that the hospital stretched its nurse-to-patient ratios beyond their limits but nurses now have protections in place to hold management accountable. 'We made sure that we have a resource nurse for every five nurses or more,' said Lorenzo, who helped negotiate the contract. 'If there's five nurses in the unit, we will have a resource nurse dedicated for that unit alone. Obviously, better staffing leads to faster response, reduces medical errors and prevents staff burnout.' Nurses are hopeful that the boosted salaries and ratio protections will go a long way toward addressing what they called inadequate staffing at the hospital. The union also proposed forming a pandemic task force following the experience of the COVID-19 pandemic that overwhelmed hospitals in Orange County. The contract guarantees that nurses will have enough personal protective equipment for three months while following U.S. Center for Disease Control and Prevention guidelines. 'We're more prepared in the case of another pandemic, as opposed to just scrambling,' Lorenzo said. As nurses also complained about broken-down MRI machines and the lack of running hot water at times, the hospital has also pledged to make timely repairs to medical equipment while addressing other maintenance issues. Lorenzo beamed with pride when speaking about critical provisions of the newly ratified contract, which arrived in less than one year's time since safety concerns first prompted nurses to unionize in August. 'Our efforts have paid off,' she said. 'Now we have our first contract. This is not only for us, but also for our patients and the community.'
